The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sivertseva S.A.

JSC «Medical and sanitary unit ”Neftyanik”»;
Ural State Medical University;
Kirov State Medical University

Novikova O.Yu.

JSC «Medical and sanitary unit ”Neftyanik”»

Chukreev V.D.

JSC «Medical and sanitary unit ”Neftyanik”»

Yurovskikh I.V.

JSC «Medical and sanitary unit ”Neftyanik”»

Belkin A.A.

Clinical Institute of Brain

Boyko A.N.

Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia

Evaluation of the effectiveness of intensive medical rehabilitation in MS patients through the prism of functional tests and serum neurofilaments

Authors:

Sivertseva S.A., Novikova O.Yu., Chukreev V.D., Yurovskikh I.V., Belkin A.A., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7‑2): 79‑83

DOI: 10.17116/jnevro202512507279

Read: 511 times

Buy for 300₽
Contact the author
Table of contents

EVALUATION OF THE EFFECTIVENESS OF INTENSIVE MEDICAL REHABILITATION IN MS PATIENTS THROUGH THE PRISM OF FUNCTIONAL TESTS AND SERUM NEUROFILAMENTS
EVALUATION OF THE EFFECTIVENESS OF INTENSIVE MEDICAL REHABILITATION IN MS PATIENTS THROUGH THE PRISM OF FUNCTIONAL TESTS AND SERUM NEUROFILAMENTS

To cite this article:

Sivertseva SA, Novikova OYu, Chukreev VD, Yurovskikh IV, Belkin AA, Boyko AN. Evaluation of the effectiveness of intensive medical rehabilitation in MS patients through the prism of functional tests and serum neurofilaments. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(7‑2):79‑83. (In Russ.)
https://doi.org/10.17116/jnevro202512507279

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Abstract:

OBJECTIVE

To evaluate the effect of intensive medical rehabilitation on serum neurofilament (NF) levels and performance in multiple sclerosis (MS) patients.

MATERIAL AND METHODS

The study included 39 patients with various forms of MS (remitting, secondary progressive, and primary progressive). Participants underwent a comprehensive assessment of motor and cognitive functions and quality of life (EDSS and Berg scales, 5STS, 6MWT, MOCA, SDMT, MSQOL-54 tests). The serum levels of NFL (NF light chains) and NFH (NF heavy chains) were measured using ELISA. The medical rehabilitation program included a 10-day inpatient course and an 8-day telerehabilitation. Follow-up measurements were performed after medical rehabilitation was completed.

RESULTS

There was no statistically significant decrease in the level of serum neurofilaments after the medical rehabilitation (p=0.686). However, there was a significant improvement in cognitive function (MoCA and SDMT scales, Beck’s inventory, p<0.01), motor performance (Berg scale, EDSS, 5STS, 6MWT, p<0.05), and quality of life. A correlation between NF level and disability indicators (EDSS) and cognitive status was found.

CONCLUSION

The study’s results confirm that intensive medical rehabilitation improves motor and cognitive functions in patients with MS but does not significantly affect the NF level, which indicates predominantly functional rather than structural changes in the nervous system. It emphasized the importance of a combined approach to MS management, including drug therapy and medical rehabilitative interventions. Studies with larger samples and more sensitive NF analysis methods, such as Simoa, are needed to further investigate the effect of medical rehabilitation on neurodegenerative processes.

Keywords:

multiple sclerosis
neurofilaments
medical rehabilitation

Authors:

Sivertseva S.A.

JSC «Medical and sanitary unit ”Neftyanik”»;
Ural State Medical University;
Kirov State Medical University

Novikova O.Yu.

JSC «Medical and sanitary unit ”Neftyanik”»

Chukreev V.D.

JSC «Medical and sanitary unit ”Neftyanik”»

Yurovskikh I.V.

JSC «Medical and sanitary unit ”Neftyanik”»

Belkin A.A.

Clinical Institute of Brain

Boyko A.N.

Federal Center for Brain and Neurotechnologies of the Federal Medical Biological Agency of Russia;
N.I. Pirogov Russian National Research Medical University (Pirogov University), Moscow, Russia

Received:

28.05.2025

Accepted:

13.06.2025

Close metadata

References:

  1. Boiko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. S.S. Korsakov Journal of Neurology and Psychiatry. Specvypuski. 2017;117(2-2):92-106. (In Russ.). https://doi.org/10.17116/jnevro20171172292-106
  2. Wandall-Holm MF, Buron MD, Kopp TI, et al. Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;93(8):858-864.  https://doi.org/10.1136/jnnp-2022-329058
  3. He A, Spelman T, Manouchehrinia A, et al. Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study. J Neurol Neurosurg Psychiatry. 2022;94(4):284-289.  https://doi.org/10.1136/jnnp-2022-330169
  4. Karampampa K, Gyllensten H, Murley C, et al. Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden. Mult Scler J. 2022;8(2):205521732210924. https://doi.org/10.1177/20552173221092411
  5. Cerqueira JJ, Compston DAS, Geraldes R, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosur Psychiatry. 2018;89(8):844-850.  https://doi.org/10.1136/jnnp-2017-317509
  6. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. T. Brain health: time matters in multiple sclerosis. Mult Scler Rel Disord. 2016;9:S5-S48.  https://doi.org/10.1016/j.msard.2016.07.003
  7. Newsome SD, Binns C, Kaunzner UW, et al. No Evidence of Disease Activity (NEDA) as a clinical assessment tool for Multiple sclerosis: Clinician and Patient Perspectives [Narrative Review]. Neurol Ther. 2023;12(6):1909-1935. https://doi.org/10.1007/s40120-023-00549-7
  8. Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler J. 2016;22(10):1297-1305. https://doi.org/10.1177/1352458515616701
  9. Lorefice L, Mellino P, Fenu G, et al. How to measure the treatment response in progressive multiple sclerosis: Current perspectives and limitations in clinical settings’. Mult Scler Relat Disord. 2023;76:104826. https://doi.org/10.1016/j.msard.2023.104826
  10. Fedičová M, Mikula P, Gdovinová Z, et al. Annual Plasma Neurofilament Dynamics Is a Sensitive Biomarker of Disease Activity in Patients with Multiple Sclerosis. Medicina. 2023;59(5):865.  https://doi.org/10.3390/medicina59050865
  11. Park Y, Kc N, Paneque A, et al. Tau, glial fibrillary acidic protein, and neurofilament light chain as brain protein biomarkers in cerebrospinal fluid and blood for diagnosis of neurobiological diseases. Int J Mol Sci. 2024;25(12):6295. https://doi.org/10.3390/ijms25126295
  12. Husseini L, Jung J, Boess N, et al. Neurofilament light chain serum levels mirror age and disability in secondary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflammation. 2024;11(5):e200279. https://doi.org/10.1212/NXI.0000000000200279
  13. Ding EA, Kumar S. Neurofilament Biophysics: from Structure to Biomechanics. Mol Biol Cell. 2024;35(5):re1.  https://doi.org/10.1091/mbc.E23-11-0438
  14. Alifirova VM, Kamenskikh EM, Koroleva ES. Evaluation of serum neurofilament light chains levels for diagnosis, treatment monitoring and prognosis in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):7-13. (In Russ.). https://doi.org/10.17116/jnevro20191191027
  15. Fox RJ, Cree BAC, de Sèze J, et al. Temporal relationship between serum neurofilament light chain and radiologic disease activity in patients with multiple sclerosis. Neurology. 2024;102(9):e209357. https://doi.org/10.1212/WNL.0000000000209357
  16. Yang J, Hamade M, Wu Q, et al. Current and future biomarkers in multiple sclerosis. Int J Mol Sci. 2022;23(11):5877. https://doi.org/10.3390/ijms23115877
  17. Ciubotaru A, Grosu C, Alexa D, et al. The faces of “Too Late”-A surprisingly progressive cohort of “Stable” relapsing remitting multiple sclerosis patients. Medicina. 2024;60(9):1401. https://doi.org/10.3390/medicina60091401
  18. Zhu W, Chen C, Zhang L, et al. Association between serum multi-protein biomarker profile and real-world disability in multiple sclerosis. Brain Commun. 2023;6(1):fcad300. https://doi.org/10.1093/braincomms/fcad300
  19. Schilke ED, Remoli G, Funelli E, et al. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials. Neurol Sci. 2023;45(5):1931-1944. https://doi.org/10.1007/s10072-023-07228-3
  20. Passali M, Galea I, Knudsen MH, et al. Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis. J Neurol. 2024;271(9):6127-6135. https://doi.org/10.1007/s00415-024-12587-8
  21. Desu HL, Sawicka KM, Wuerch E, et al. A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis. Front Neurol. 2024;15:1382468. https://doi.org/10.3389/fneur.2024.1382468
  22. Revendova KZ, Zeman D, Bunganic R, et al. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels. Mult Scler Relat Disord. 2022;67:104177. https://doi.org/10.1016/j.msard.2022.104177
  23. Koerbel K, Maiworm M, Schaller-Paule M, et al. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis. Mult Scler Relat Disord. 2024;87:105644. https://doi.org/10.1016/j.msard.2024.105644
  24. Højsgaard Chow H, Petersen ER, Olsson A, et al. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment. Mult Scler Relat Disord. 2024;88:105701. https://doi.org/10.1016/j.msard.2024.105701
  25. Barrero Hernández FJ, Romero Villarrubia A, Muñoz Fernández C, et al. Real-World Study of Serum Neurofilament Light Chain Levels in Ocrelizumab-Treated People with Relapsing Multiple Sclerosis. J Person Med. 2024;14(7):692.  https://doi.org/10.3390/jpm14070692
  26. Stork L, Haupts M, Kruse N, et al. Serum neurofilament light chains in progressive multiple sclerosis patients treated with repeated cycles of high-dose intravenous steroids. PubMed. 2023;4:4-15.  https://doi.org/10.17879/freeneuropathology-2023-5049
  27. Delcoigne B, Manouchehrinia A, Barro C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology. 2020;94(11):e1201-e1212. https://doi.org/10.1212/WNL.0000000000009097
  28. Sainz-Amo R, Rodero A, Romero A, et al. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. Front Immunol. 2024;15.  https://doi.org/10.3389/fimmu.2024.1454474
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.